{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:52:40Z","timestamp":1787590360105,"version":"build-2736575974"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-025-04434-3","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T08:44:44Z","timestamp":1756716284000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Taming renal inflammation: signaling pathways and therapeutic advances in lupus nephritis"],"prefix":"10.1186","volume":"26","author":[{"given":"Marsela","family":"Braunstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"issue":"2","key":"4434_CR1","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1053\/j.ajkd.2019.10.017","volume":"76","author":"SV Parikh","year":"2020","unstructured":"Parikh SV, Almaani S, Brodsky S, Rovin BH. Update on lupus nephritis: core curriculum 2020. Am J Kidney Dis. 2020;76(2):265\u201381.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"4434_CR2","doi-asserted-by":"publisher","first-page":"16021","DOI":"10.1038\/ncomms16021","volume":"8","author":"CD Langefeld","year":"2017","unstructured":"Langefeld CD, Ainsworth HC, Graham DSC, Kelly JA, Comeau ME, Marion MC, et al. Transancestral mapping and genetic load in systemic lupus erythematosus. Nat Commun. 2017;8(1):16021.","journal-title":"Nat Commun"},{"issue":"9","key":"4434_CR3","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1136\/annrheumdis-2022-222345","volume":"81","author":"X Yin","year":"2022","unstructured":"Yin X, Kim K, Suetsugu H, Bang SY, Wen L, Koido M, et al. Biological insights into systemic lupus erythematosus through an immune cell-specific transcriptome-wide association study. Ann Rheum Dis. 2022;81(9):1273\u201380.","journal-title":"Ann Rheum Dis"},{"key":"4434_CR4","doi-asserted-by":"publisher","first-page":"5902","DOI":"10.1038\/ncomms6902","volume":"5","author":"K Kim","year":"2014","unstructured":"Kim K, Bang SY, Lee HS, Okada Y, Han B, Saw WY, et al. The HLA-DR\u03b21 amino acid positions 11-13-26 explain the majority of SLE-MHC associations. Nat Commun. 2014;5:5902.","journal-title":"Nat Commun"},{"issue":"12","key":"4434_CR5","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/nrrheum.2016.186","volume":"12","author":"GC Tsokos","year":"2016","unstructured":"Tsokos GC, Lo MS, Reis PC, Sullivan KE. New insights into the Immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol. 2016;12(12):716\u201330.","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"4434_CR6","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/art.42375","volume":"75","author":"M Hocaoglu","year":"2023","unstructured":"Hocaoglu M, Valenzuela-Almada MO, Dabit JY, Osei-Onomah SA, Chevet B, Giblon RE, et al. Incidence, prevalence, and mortality of lupus nephritis: A Population-Based study over four Decades\u2014The lupus Midwest network (LUMEN). Arthritis Rheumatol. 2023;75(4):567\u201373.","journal-title":"Arthritis Rheumatol"},{"issue":"1S","key":"4434_CR7","first-page":"S1","volume":"105","author":"Kidney Disease","year":"2024","unstructured":"Kidney Disease. Improving global outcomes (KDIGO) lupus nephritis work group. KDIGO 2024 clinical practice guideline for the management of LUPUS NEPHRITIS. Kidney Int. 2024;105(1S):S1\u201369.","journal-title":"Kidney Int"},{"issue":"7","key":"4434_CR8","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/s41590-019-0398-x","volume":"20","author":"A Arazi","year":"2019","unstructured":"Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ, et al. The immune cell landscape in kidneys of patients with lupus nephritis. Nat Immunol. 2019;20(7):902\u201314.","journal-title":"Nat Immunol"},{"issue":"7","key":"4434_CR9","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/nrneph.2016.71","volume":"12","author":"S Gupta","year":"2016","unstructured":"Gupta S, Kaplan MJ. The role of neutrophils and NETosis in autoimmune and renal diseases. Nat Rev Nephrol. 2016;12(7):402\u201313.","journal-title":"Nat Rev Nephrol"},{"key":"4434_CR10","doi-asserted-by":"publisher","unstructured":"Wang X, Chen J, Xu J, Xie J, Harris DCH, Zheng G. The role of macrophages in kidney fibrosis. Front Physiol [Internet]. 2021 Aug 6 [cited 2025 Feb 25];12. Available from: https:\/\/www.frontiersin.org\/journals\/physiology\/articles\/https:\/\/doi.org\/10.3389\/fphys.2021.705838\/full","DOI":"10.3389\/fphys.2021.705838\/full"},{"issue":"2","key":"4434_CR11","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.immuni.2015.07.016","volume":"43","author":"J Sheng","year":"2015","unstructured":"Sheng J, Ruedl C, Karjalainen K. Most Tissue-Resident macrophages except microglia are derived from fetal hematopoietic stem cells. Immunity. 2015;43(2):382\u201393.","journal-title":"Immunity"},{"key":"4434_CR12","doi-asserted-by":"crossref","unstructured":"Richoz N, Tuong ZK, Loudon KW, Pati\u00f1o-Mart\u00ednez E, Ferdinand JR, Romo-Tena J et al. Distinct pathogenic roles for resident and monocyte-derived macrophages in lupus nephritis. JCI Insight [Internet]. 2023 May 2 [cited 2025 Feb 20];7(21). Available from: https:\/\/insight.jci.org\/articles\/view\/159751#B11","DOI":"10.1172\/jci.insight.159751"},{"issue":"7","key":"4434_CR13","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/acr2.11269","volume":"3","author":"A Davidson","year":"2021","unstructured":"Davidson A. Renal mononuclear phagocytes in lupus nephritis. ACR Open Rheumatol. 2021;3(7):442\u201350.","journal-title":"ACR Open Rheumatol"},{"issue":"2","key":"4434_CR14","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.kint.2016.08.020","volume":"91","author":"MZ Zhang","year":"2017","unstructured":"Zhang MZ, Wang X, Wang Y, Niu A, Wang S, Zou C, et al. IL-4\/IL-13-mediated polarization of renal macrophages\/dendritic cells to an M2a phenotype is essential for recovery from acute kidney injury. Kidney Int. 2017;91(2):375\u201386.","journal-title":"Kidney Int"},{"issue":"12","key":"4434_CR15","doi-asserted-by":"publisher","first-page":"e0143961","DOI":"10.1371\/journal.pone.0143961","volume":"10","author":"MG Kim","year":"2015","unstructured":"Kim MG, Kim SC, Ko YS, Lee HY, Jo SK, Cho W. The role of M2 macrophages in the progression of chronic kidney disease following acute kidney injury. PLoS ONE. 2015;10(12):e0143961.","journal-title":"PLoS ONE"},{"key":"4434_CR16","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13075-016-0989-y","volume":"18","author":"G Olmes","year":"2016","unstructured":"Olmes G, B\u00fcttner-Herold M, Ferrazzi F, Distel L, Amann K, Daniel C. CD163\u2009+\u2009M2c-like macrophages predominate in renal biopsies from patients with lupus nephritis. Arthritis Res Ther. 2016;18:90.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"4434_CR17","doi-asserted-by":"publisher","first-page":"534","DOI":"10.4172\/2155-9899.1000534","volume":"8","author":"LM Davison","year":"2017","unstructured":"Davison LM, Jorgensen TN. New treatments for systemic lupus erythematosus on the horizon: targeting plasmacytoid dendritic cells to inhibit cytokine production. J Clin Cell Immunol. 2017;8(6):534.","journal-title":"J Clin Cell Immunol"},{"issue":"1","key":"4434_CR18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/ki.2008.99","volume":"74","author":"S Segerer","year":"2008","unstructured":"Segerer S, Heller F, Lindenmeyer MT, Schmid H, Cohen CD, Draganovici D, et al. Compartment specific expression of dendritic cell markers in human glomerulonephritis. Kidney Int. 2008;74(1):37\u201346.","journal-title":"Kidney Int"},{"issue":"8035","key":"4434_CR19","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/s41586-024-07907-x","volume":"634","author":"SI Biniaris-Georgallis","year":"2024","unstructured":"Biniaris-Georgallis SI, Aschman T, Stergioula K, Schreiber F, Jafari V, Taranko A, et al. Amplification of autoimmune organ damage by NKp46-activated ILC1s. Nature. 2024;634(8035):952\u201360.","journal-title":"Nature"},{"key":"4434_CR20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1136\/annrheumdis-2015-eular.4965","volume":"74","author":"J Wither","year":"2015","unstructured":"Wither J, Prokopec S, Noamani B, Bonilla D, Touma Z, Reich H, et al. OP0091 A low density granulocyte gene expression signature distinguishes between active patients with and without nephritis in systemic lupus erythematosus (SLE). Ann Rheum Dis. 2015;74:103.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"4434_CR21","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s00281-013-0375-7","volume":"35","author":"C Carmona-Rivera","year":"2013","unstructured":"Carmona-Rivera C, Kaplan MJ. Low density granulocytes: a distinct class of neutrophils in systemic autoimmunity. Semin Immunopathol. 2013;35(4):455\u201363.","journal-title":"Semin Immunopathol"},{"issue":"6","key":"4434_CR22","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nrneph.2017.34","volume":"13","author":"A Su\u00e1rez-Fueyo","year":"2017","unstructured":"Su\u00e1rez-Fueyo A, Bradley SJ, Klatzmann D, Tsokos GC. T cells and autoimmune kidney disease. Nat Rev Nephrol. 2017;13(6):329\u201343.","journal-title":"Nat Rev Nephrol"},{"key":"4434_CR23","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.clim.2016.04.010","volume":"185","author":"T Koga","year":"2017","unstructured":"Koga T, Ichinose K, Tsokos GC. T cells and IL-17 in lupus nephritis. Clin Immunol. 2017;185:95\u20139.","journal-title":"Clin Immunol"},{"issue":"6","key":"4434_CR24","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1097\/BOR.0000000000000815","volume":"33","author":"PM Chen","year":"2021","unstructured":"Chen PM, Tsokos GC. The role of CD8\u2009+\u2009T-cell systemic lupus erythematosus pathogenesis: an update. Curr Opin Rheumatol. 2021;33(6):586\u201391.","journal-title":"Curr Opin Rheumatol"},{"issue":"9","key":"4434_CR25","doi-asserted-by":"publisher","first-page":"4207","DOI":"10.4049\/jimmunol.1402775","volume":"194","author":"N Rodr\u00edguez-Rodr\u00edguez","year":"2015","unstructured":"Rodr\u00edguez-Rodr\u00edguez N, Apostolidis SA, Penaloza-MacMaster P, Mart\u00edn Villa JM, Barouch DH, Tsokos GC, et al. Programmed cell death 1 and helios distinguish TCR-\u03b1\u03b2\u2009+\u2009double-negative (CD4-CD8-) T cells that derive from self-reactive CD8 T cells. J Immunol. 2015;194(9):4207\u201314.","journal-title":"J Immunol"},{"issue":"12","key":"4434_CR26","doi-asserted-by":"publisher","first-page":"8761","DOI":"10.4049\/jimmunol.181.12.8761","volume":"181","author":"JC Crisp\u00edn","year":"2008","unstructured":"Crisp\u00edn JC, Oukka M, Bayliss G, Cohen RA, Van Beek CA, Stillman IE, et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol. 2008;181(12):8761\u20136.","journal-title":"J Immunol"},{"issue":"3","key":"4434_CR27","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.4049\/jimmunol.1001983","volume":"186","author":"A Chang","year":"2011","unstructured":"Chang A, Henderson SG, Brandt D, Liu N, Guttikonda R, Hsieh C, et al. In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. J Immunol. 2011;186(3):1849\u201360.","journal-title":"J Immunol"},{"issue":"5","key":"4434_CR28","doi-asserted-by":"publisher","first-page":"e20221346","DOI":"10.1084\/jem.20221346","volume":"220","author":"KM Nickerson","year":"2023","unstructured":"Nickerson KM, Smita S, Hoehn KB, Marinov AD, Thomas KB, Kos JT, et al. Age-associated B cells are heterogeneous and dynamic drivers of autoimmunity in mice. J Exp Med. 2023;220(5):e20221346.","journal-title":"J Exp Med"},{"issue":"5","key":"4434_CR29","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1177\/0961203317739132","volume":"27","author":"JP Suso","year":"2018","unstructured":"Suso JP, Posso-Osorio I, Jim\u00e9nez CA, Naranjo-Escobar J, Ospina FE, S\u00e1nchez A, et al. Profile of BAFF and its receptors\u2019 expression in lupus nephritis is associated with pathological classes. Lupus. 2018;27(5):708\u201315.","journal-title":"Lupus"},{"key":"4434_CR30","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.3389\/fimmu.2019.02061","volume":"10","author":"JS Verbeek","year":"2019","unstructured":"Verbeek JS, Hirose S, Nishimura H. The complex association of Fc\u03b3RIIb with autoimmune susceptibility. Front Immunol. 2019;10:2061.","journal-title":"Front Immunol"},{"key":"4434_CR31","doi-asserted-by":"crossref","unstructured":"Ramsey-Goldman R, Li J, Dervieux T, Alexander RV. Cell-bound complement activation products in SLE. Lupus Sci Med [Internet]. 2017 Aug 21 [cited 2025 Mar 4];4(1). Available from: https:\/\/lupus.bmj.com\/content\/4\/1\/e000236","DOI":"10.1136\/lupus-2017-000236"},{"issue":"8","key":"4434_CR32","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1177\/0961203316645205","volume":"25","author":"G Stojan","year":"2016","unstructured":"Stojan G, Petri M. Anti-C1q in systemic lupus erythematosus. Lupus. 2016;25(8):873\u20137.","journal-title":"Lupus"},{"key":"4434_CR33","doi-asserted-by":"publisher","first-page":"676082","DOI":"10.3389\/fimmu.2021.676082","volume":"12","author":"X Ding","year":"2021","unstructured":"Ding X, Ren Y, He X. IFN-I mediates lupus nephritis from the beginning to renal fibrosis. Front Immunol. 2021;12:676082.","journal-title":"Front Immunol"},{"issue":"1 0 1","key":"4434_CR34","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.gene.2015.09.058","volume":"576","author":"CML de Padilla","year":"2016","unstructured":"de Padilla CML, Niewold TB, The Type I, Interferons. Basic concepts and clinical relevance in Immune-mediated inflammatory diseases. Gene. 2016;576(1 0 1):14\u201321.","journal-title":"Gene"},{"issue":"9","key":"4434_CR35","doi-asserted-by":"publisher","first-page":"963","DOI":"10.3390\/cells8090963","volume":"8","author":"IT Chyuan","year":"2019","unstructured":"Chyuan IT, Tzeng HT, Chen JY. Signaling pathways of type I and type III interferons and targeted therapies in systemic lupus erythematosus. Cells. 2019;8(9):963.","journal-title":"Cells"},{"issue":"3","key":"4434_CR36","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.cell.2016.03.008","volume":"165","author":"R Banchereau","year":"2016","unstructured":"Banchereau R, Hong S, Cantarel B, Baldwin N, Baisch J, Edens M, et al. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell. 2016;165(3):551\u201365.","journal-title":"Cell"},{"issue":"8","key":"4434_CR37","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/s41581-023-00722-z","volume":"19","author":"C Mohan","year":"2023","unstructured":"Mohan C, Zhang T, Putterman C. Pathogenic cellular and molecular mediators in lupus nephritis. Nat Rev Nephrol. 2023;19(8):491\u2013508.","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"4434_CR38","doi-asserted-by":"publisher","first-page":"e000910","DOI":"10.1136\/lupus-2023-000910","volume":"10","author":"D Jayne","year":"2023","unstructured":"Jayne D, Rovin B, Mysler E, Furie R, Houssiau F, Trasieva T, et al. Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial. Lupus Sci Med. 2023;10(2):e000910.","journal-title":"Lupus Sci Med"},{"issue":"4","key":"4434_CR39","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1136\/annrheumdis-2021-221478","volume":"81","author":"D Jayne","year":"2022","unstructured":"Jayne D, Rovin B, Mysler EF, Furie RA, Houssiau FA, Trasieva T, et al. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann Rheum Dis. 2022;81(4):496\u2013506.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"4434_CR40","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1053\/j.ackd.2019.09.001","volume":"26","author":"DJ Caster","year":"2019","unstructured":"Caster DJ, Powell DW. Utilization of biomarkers in lupus nephritis. Adv Chronic Kidney Dis. 2019;26(5):351\u20139.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"12","key":"4434_CR41","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","volume":"383","author":"R Furie","year":"2020","unstructured":"Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, et al. Two-Year, randomized, controlled trial of Belimumab in lupus nephritis. N Engl J Med. 2020;383(12):1117\u201328.","journal-title":"N Engl J Med"},{"issue":"4","key":"4434_CR42","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1177\/09612033221079771","volume":"31","author":"T Liu","year":"2022","unstructured":"Liu T, Neuner R, Thompson A, Pottackal G, Petullo D, Liu J, et al. Clinical Pharmacology considerations for the approval of Belimumab for the treatment of adult patients with active lupus nephritis: A regulatory perspective. Lupus. 2022;31(4):424\u201332.","journal-title":"Lupus"},{"issue":"12","key":"4434_CR43","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.7326\/M21-2078","volume":"174","author":"M Shipa","year":"2021","unstructured":"Shipa M, Embleton-Thirsk A, Parvaz M, Santos LR, Muller P, Chowdhury K, et al. Effectiveness of Belimumab after rituximab in systemic lupus erythematosus: A randomized controlled trial. Ann Intern Med. 2021;174(12):1647\u201357.","journal-title":"Ann Intern Med"},{"issue":"1","key":"4434_CR44","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1186\/s13063-022-06874-w","volume":"23","author":"M van Schaik","year":"2022","unstructured":"van Schaik M, Arends EJ, Soonawala D, van Ommen E, de Leeuw K, Limper M, et al. Efficacy of Belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label synbiose 2 trial. Trials. 2022;23(1):939.","journal-title":"Trials"},{"issue":"1","key":"4434_CR45","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.27233","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Efficacy and safety of rituximab in Moderately-to-Severely active systemic lupus erythematosus. Arthritis Rheum. 2010;62(1):222\u201333.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"4434_CR46","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.2215\/CJN.01070118","volume":"13","author":"LMG Mendez","year":"2018","unstructured":"Mendez LMG, Cascino MD, Garg J, Katsumoto TR, Brakeman P, Dall\u2019era M, et al. Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis. Clin J Am Soc Nephrol. 2018;13(10):1502\u20139.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"4434_CR47","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1136\/annrheumdis-2012-202844","volume":"72","author":"MB Condon","year":"2013","unstructured":"Condon MB, Ashby D, Pepper RJ, Cook HT, Levy JB, Griffith M, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis. 2013;72(8):1280\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"15","key":"4434_CR48","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","volume":"392","author":"RA Furie","year":"2025","unstructured":"Furie RA, Rovin BH, Garg JP, Santiago MB, Aroca-Mart\u00ednez G, Santill\u00e1n AEZ, et al. Efficacy and safety of obinutuzumab in active lupus nephritis. N Engl J Med. 2025;392(15):1471\u201383.","journal-title":"N Engl J Med"},{"issue":"1","key":"4434_CR49","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","volume":"81","author":"RA Furie","year":"2022","unstructured":"Furie RA, Aroca G, Cascino MD, Garg JP, Rovin BH, Alvarez A, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2022;81(1):100\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"4434_CR50","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1056\/NEJMoa2023325","volume":"383","author":"L Ostendorf","year":"2020","unstructured":"Ostendorf L, Burns M, Durek P, Heinz GA, Heinrich F, Garantziotis P, et al. Targeting CD38 with daratumumab in refractory systemic lupus erythematosus. N Engl J Med. 2020;383(12):1149\u201355.","journal-title":"N Engl J Med"},{"issue":"12","key":"4434_CR51","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1007\/s00296-023-05389-0","volume":"43","author":"E Calatayud","year":"2023","unstructured":"Calatayud E, Montomoli M, \u00c1vila A, Sancho Calabuig A, Alegre-Sancho JJ. Experience with abatacept in refractory lupus nephritis. Rheumatol Int. 2023;43(12):2319\u201326.","journal-title":"Rheumatol Int"},{"key":"4434_CR52","unstructured":"Clinical Safety and Efficacy Results from EQUALISE Type B. A Phase 1b Open-label Clinical Study of Itolizumab, a Novel anti-CD6 Therapy, in Subjects with Active Proliferative Lupus Nephritis [Internet]. ACR Meeting Abstracts. [cited 2025 Jul 6]. Available from: https:\/\/acrabstracts.org\/abstract\/clinical-safety-and-efficacy-results-from-equalise-type-b-a-phase-1b-open-label-clinical-study-of-itolizumab-a-novel-anti-cd6-therapy-in-subjects-with-active-proliferative-lupus-nephritis\/"},{"issue":"10289","key":"4434_CR53","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","volume":"397","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Teng YKO, Ginzler EM, Arriens C, Caster DJ, Romero-Diaz J, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021;397(10289):2070\u201380.","journal-title":"Lancet"},{"issue":"12","key":"4434_CR54","doi-asserted-by":"publisher","first-page":"103440","DOI":"10.1016\/j.autrev.2023.103440","volume":"22","author":"L Ma","year":"2023","unstructured":"Ma L, Peng L, Zhao J, Bai W, Jiang N, Zhang S, et al. Efficacy and safety of Janus kinase inhibitors in systemic and cutaneous lupus erythematosus: A systematic review and meta-analysis. Autoimmun Rev. 2023;22(12):103440.","journal-title":"Autoimmun Rev"},{"key":"4434_CR55","doi-asserted-by":"crossref","unstructured":"Torun ES. Efficacy and safety of janus kinase inhibitors in lupus nephritis patients- clinical trials and case reports. Medical Research Archives [Internet]. 2025 Jan 2 [cited 2025 May 6];12(12). Available from: https:\/\/esmed.org\/MRA\/mra\/article\/view\/6221","DOI":"10.18103\/mra.v12i12.6221"},{"issue":"3","key":"4434_CR56","doi-asserted-by":"publisher","first-page":"e001490","DOI":"10.1136\/rmdopen-2020-001490","volume":"6","author":"M Baker","year":"2020","unstructured":"Baker M, Chaichian Y, Genovese M, Derebail V, Rao P, Chatham W, et al. Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and Lanraplenib in patients with lupus membranous nephropathy. RMD Open. 2020;6(3):e001490.","journal-title":"RMD Open"},{"issue":"4","key":"4434_CR57","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1053\/j.ajkd.2013.11.023","volume":"63","author":"BH Rovin","year":"2014","unstructured":"Rovin BH, Parikh SV. Lupus nephritis: the evolving role of novel therapeutics. Am J Kidney Dis. 2014;63(4):677\u201390.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"4434_CR58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-022-00772-9","volume":"13","author":"CS Tam","year":"2023","unstructured":"Tam CS, Mu\u00f1oz JL, Seymour JF, Opat S. Zanubrutinib: past, present, and future. Blood Cancer J. 2023;13(1):1\u201313.","journal-title":"Blood Cancer J"},{"key":"4434_CR59","doi-asserted-by":"publisher","first-page":"1476859","DOI":"10.3389\/fimmu.2024.1476859","volume":"15","author":"J Zhou","year":"2024","unstructured":"Zhou J, Lei B, Shi F, Luo X, Wu K, Xu Y, et al. CAR T-cell therapy for systemic lupus erythematosus: current status and future perspectives. Front Immunol. 2024;15:1476859.","journal-title":"Front Immunol"},{"issue":"10","key":"4434_CR60","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen A, M\u00fcller F, Mougiakakos D, B\u00f6ltz S, Wilhelm A, Aigner M, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022;28(10):2124\u201332.","journal-title":"Nat Med"},{"issue":"8","key":"4434_CR61","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, V\u00f6lkl S, et al. CD19 CAR T-Cell therapy in autoimmune Disease - A case series with Follow-up. N Engl J Med. 2024;390(8):687\u2013700.","journal-title":"N Engl J Med"},{"key":"4434_CR62","unstructured":"Honaker Y, Gruber D, Jacobs C, Yu-Hong Cheng R, Patel S, Galvan CZ et al. Targeting human plasma cells using regulated BCMA CAR T cells eliminates circulating antibodies in humanized mice. Molecular Therapy [Internet]. 2024 Dec 12 [cited 2025 May 11]; Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1525001624008177"},{"key":"4434_CR63","doi-asserted-by":"publisher","first-page":"1447147","DOI":"10.3389\/fmed.2024.1447147","volume":"11","author":"J Vukovic","year":"2024","unstructured":"Vukovic J, Abazovic D, Vucetic D, Medenica S. CAR-engineered T cell therapy as an emerging strategy for treating autoimmune diseases. Front Med (Lausanne). 2024;11:1447147.","journal-title":"Front Med (Lausanne)"},{"key":"4434_CR64","doi-asserted-by":"publisher","first-page":"1721727X2210787","DOI":"10.1177\/1721727X221078727","volume":"20","author":"X Shi","year":"2022","unstructured":"Shi X, Wu H. Recent advances in the prevention and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy. Eur J Inflamm. 2022;20:1721727X221078727.","journal-title":"Eur J Inflamm"},{"key":"4434_CR65","doi-asserted-by":"publisher","unstructured":"Sainatham C, Yadav D, Dilli Babu A, Tallapalli JR, Kanagala SG, Filippov E et al. The current socioeconomic and regulatory landscape of immune effector cell therapies. Front Med [Internet]. 2024 Dec 4 [cited 2025 Jul 6];11. Available from: https:\/\/www.frontiersin.org\/journals\/medicine\/articles\/https:\/\/doi.org\/10.3389\/fmed.2024.1462307\/full","DOI":"10.3389\/fmed.2024.1462307\/full"},{"issue":"6","key":"4434_CR66","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1097\/BOR.0000000000000738","volume":"32","author":"J Romo-Tena","year":"2020","unstructured":"Romo-Tena J, Kaplan MJ. Immunometabolism in the pathogenesis of systemic lupus erythematosus: an update. Curr Opin Rheumatol. 2020;32(6):562\u201371.","journal-title":"Curr Opin Rheumatol"},{"issue":"6","key":"4434_CR67","doi-asserted-by":"publisher","first-page":"R127","DOI":"10.1186\/ar2541","volume":"10","author":"PS Reddy","year":"2008","unstructured":"Reddy PS, Legault HM, Sypek JP, Collins MJ, Goad E, Goldman SJ, et al. Mapping similarities in mTOR pathway perturbations in mouse lupus nephritis models and human lupus nephritis. Arthritis Res Therapy. 2008;10(6):R127.","journal-title":"Arthritis Res Therapy"},{"issue":"26","key":"4434_CR68","doi-asserted-by":"publisher","first-page":"15160","DOI":"10.1073\/pnas.2000943117","volume":"117","author":"C Jing","year":"2020","unstructured":"Jing C, Castro-Dopico T, Richoz N, Tuong ZK, Ferdinand JR, Lok LSC, et al. Macrophage metabolic reprogramming presents a therapeutic target in lupus nephritis. Proc Natl Acad Sci U S A. 2020;117(26):15160\u201371.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"4434_CR69","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13148-017-0378-7","volume":"9","author":"Z Wang","year":"2017","unstructured":"Wang Z, Chang C, Peng M, Lu Q. Translating epigenetics into clinic: focus on lupus. Clin Epigenetics. 2017;9(1):78.","journal-title":"Clin Epigenetics"},{"key":"4434_CR70","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40348-023-00157-3","volume":"10","author":"V Bruno","year":"2023","unstructured":"Bruno V, M\u00fchlig AK, Oh J, Licht C. New insights into the immune functions of podocytes: the role of complement. Mol Cell Pediatr. 2023;10:3.","journal-title":"Mol Cell Pediatr"},{"issue":"12","key":"4434_CR71","doi-asserted-by":"publisher","first-page":"5298","DOI":"10.1172\/JCI71165","volume":"123","author":"T Schaldecker","year":"2013","unstructured":"Schaldecker T, Kim S, Tarabanis C, Tian D, Hakroush S, Castonguay P, et al. Inhibition of the TRPC5 ion channel protects the kidney filter. J Clin Invest. 2013;123(12):5298\u2013309.","journal-title":"J Clin Invest"},{"key":"4434_CR72","doi-asserted-by":"publisher","first-page":"721865","DOI":"10.3389\/fmed.2021.721865","volume":"8","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Kim C, Pablo JLB, Zhang F, Jung JY, Xiao L, et al. TRPC5 channel Inhibition protects podocytes in Puromycin-Aminonucleoside induced nephrosis models. Front Med (Lausanne). 2021;8:721865.","journal-title":"Front Med (Lausanne)"},{"issue":"9","key":"4434_CR73","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1007\/s11255-023-03539-8","volume":"55","author":"H Hammad","year":"2023","unstructured":"Hammad H, Shaaban A, Philips MV, Fayed A, Abdelaziz TS. Effect of sodium\u2013glucose transporter 2 inhibitor empagliflozin on proteinuria and kidney function progression in patients with non-diabetic glomerulonephritis: a pilot superiority randomized controlled trial. Int Urol Nephrol. 2023;55(9):2321\u20136.","journal-title":"Int Urol Nephrol"},{"issue":"3","key":"4434_CR74","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/BOR.0000000000001002","volume":"36","author":"BR Wagner","year":"2024","unstructured":"Wagner BR, Rao PS. Sodium-glucose cotransporter 2 inhibitors: are they ready for prime time in the management of lupus nephritis? Curr Opin Rheumatol. 2024;36(3):163\u20138.","journal-title":"Curr Opin Rheumatol"},{"key":"4434_CR75","doi-asserted-by":"crossref","unstructured":"Zhan K, Buhler KA, Chen IY, Fritzler MJ, Choi MY. Systemic lupus in the era of machine learning medicine. Lupus Sci Med [Internet]. 2024 Mar 4 [cited 2025 May 9];11(1). Available from: https:\/\/lupus.bmj.com\/content\/11\/1\/e001140","DOI":"10.1136\/lupus-2023-001140"},{"issue":"5","key":"4434_CR76","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/art.42023","volume":"74","author":"A Fava","year":"2022","unstructured":"Fava A, Rao DA, Mohan C, Zhang T, Rosenberg A, Fenaroli P, et al. Urine proteomics and renal single cell transcriptomics implicate IL-16 in lupus nephritis. Arthritis Rheumatol. 2022;74(5):829\u201339.","journal-title":"Arthritis Rheumatol"},{"key":"4434_CR77","doi-asserted-by":"publisher","first-page":"103134","DOI":"10.1016\/j.jaut.2023.103134","volume":"142","author":"JA Reynolds","year":"2024","unstructured":"Reynolds JA, Li Y, Herlitz L, Mohan C, Putterman C. Novel biomarker discovery through comprehensive proteomic analysis of lupus mouse serum. J Autoimmun. 2024;142:103134.","journal-title":"J Autoimmun"},{"issue":"18","key":"4434_CR78","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.1016\/j.cell.2022.07.021","volume":"185","author":"M Nakano","year":"2022","unstructured":"Nakano M, Ota M, Takeshima Y, Iwasaki Y, Hatano H, Nagafuchi Y, et al. Distinct transcriptome architectures underlying lupus establishment and exacerbation. Cell. 2022;185(18):3375\u2013e338921.","journal-title":"Cell"},{"issue":"7","key":"4434_CR79","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1093\/rheumatology\/keaa767","volume":"60","author":"M Bruschi","year":"2021","unstructured":"Bruschi M, Moroni G, Sinico RA, Franceschini F, Fredi M, Vaglio A, et al. Serum IgG2 antibody multicomposition in systemic lupus erythematosus and lupus nephritis (Part 1): cross-sectional analysis. Rheumatology (Oxford). 2021;60(7):3176\u201388.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"4434_CR80","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1681\/ASN.2014050493","volume":"26","author":"M Bruschi","year":"2015","unstructured":"Bruschi M, Galetti M, Sinico RA, Moroni G, Bonanni A, Radice A, et al. Glomerular autoimmune multicomponents of human lupus nephritis in vivo (2): planted antigens. J Am Soc Nephrol. 2015;26(8):1905\u201324.","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"4434_CR81","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1681\/ASN.2013090987","volume":"25","author":"M Bruschi","year":"2014","unstructured":"Bruschi M, Sinico RA, Moroni G, Pratesi F, Migliorini P, Galetti M, et al. Glomerular autoimmune multicomponents of human lupus nephritis in vivo: \u03b1-Enolase and Annexin AI. J Am Soc Nephrol. 2014;25(11):2483\u201398.","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"4434_CR82","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.autrev.2015.04.004","volume":"14","author":"A Bonanni","year":"2015","unstructured":"Bonanni A, Vaglio A, Bruschi M, Sinico RA, Cavagna L, Moroni G, et al. Multi-antibody composition in lupus nephritis: isotype and antigen specificity make the difference. Autoimmun Rev. 2015;14(8):692\u2013702.","journal-title":"Autoimmun Rev"},{"issue":"4","key":"4434_CR83","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.berh.2009.01.008","volume":"23","author":"CC Liu","year":"2009","unstructured":"Liu CC, Ahearn JM. The search for lupus biomarkers. Best Pract Res Clin Rheumatol. 2009;23(4):507\u201323.","journal-title":"Best Pract Res Clin Rheumatol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04434-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04434-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04434-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:19:27Z","timestamp":1756901967000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-04434-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4434"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04434-3","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"assertion":[{"value":"11 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is a review and does not contain any primary studies with human participants or animals; as such, ethics approval was not required for this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The study is not a clinical trial; clinical trial number is not applicable. The author had no access to the clinical trials referenced in the paper; all clinical trial information was obtained from publicly available data on clinicaltrials.gov. The consent was not required for this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial registration"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"507"}}